CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade ALX Oncology Holdings Inc. - ALXO CFD

7.99
4.77%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.11
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 8.39
Open 8.32
1-Year Change -10.73%
Day's Range 7.95 - 8.32
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 14, 2024 7.99 -0.32 -3.85% 8.31 8.35 7.94
Jun 13, 2024 8.39 -0.17 -1.99% 8.56 8.63 8.30
Jun 12, 2024 8.48 -0.14 -1.62% 8.62 8.87 8.32
Jun 11, 2024 8.50 -0.04 -0.47% 8.54 8.69 8.26
Jun 10, 2024 8.63 0.05 0.58% 8.58 8.92 8.56
Jun 7, 2024 8.97 -0.02 -0.22% 8.99 9.30 8.72
Jun 6, 2024 9.22 0.57 6.59% 8.65 9.23 8.52
Jun 5, 2024 8.74 0.22 2.58% 8.52 9.24 8.31
Jun 4, 2024 8.31 -0.43 -4.92% 8.74 8.77 8.11
Jun 3, 2024 8.90 -1.71 -16.12% 10.61 10.83 8.40
May 31, 2024 10.56 0.02 0.19% 10.54 11.00 10.34
May 30, 2024 10.59 -0.54 -4.85% 11.13 11.13 10.58
May 29, 2024 11.11 -1.16 -9.45% 12.27 12.37 10.98
May 28, 2024 12.50 -0.64 -4.87% 13.14 13.27 12.44
May 24, 2024 13.11 -1.54 -10.51% 14.65 15.11 12.95
May 23, 2024 14.63 0.05 0.34% 14.58 15.26 13.98
May 22, 2024 14.97 1.47 10.89% 13.50 15.00 13.50
May 21, 2024 13.58 -0.08 -0.59% 13.66 14.14 13.26
May 20, 2024 13.75 0.00 0.00% 13.75 14.08 13.66
May 17, 2024 14.16 -0.15 -1.05% 14.31 14.65 14.08

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

ALX Oncology Holdings Inc. Company profile

About ALX Oncology Holdings Inc

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on enabling patients to fight cancer by developing therapies that block the cluster of differentiation 47 (CD47) checkpoint pathway and bridge the innate and adaptive immune system. The Company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, ALX148, is a CD47 blocking therapeutic. ALX148 is a fusion protein that combines a CD47 binding domain with its inactivated fragment crystallizable (Fc) domain. The CD47 binding domain of ALX148 is an affinity enhanced extracellular domain of signal regulatory protein alpha (SIRPa), a protein that is the natural receptor to CD47 found on myeloid cells. Its programs are focused on targeting CD47 across various oncology indications.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, ALX Oncology Holdings Inc revenues decreased from $1.2M to $0K. Net loss applicable to common stockholders increased 64% to $83.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Reserach and developement increase of 76% to $46.5M (expense).

Industry: Bio Therapeutic Drugs

323 Allerton Avenue
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

News

Bank of Japan Preview: Markets look for guidance from BOJ about timing of next hike

The Bank of Japan meets on Friday, 14th of June, 2024. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

11:05, 12 June 2024

FOMC preview: Still expecting three rate cuts in 2024?

The Federal Reserve is expected to keep its policy unchanged on Wednesday – data from Reuters shows a 99% chance of no change. Last week’s 25-basis-point rate cut from the ECB has done nothing to change market expectations, and why should it?

08:20, 11 June 2024

US Non-Farm Payrolls Preview: Forecasts point to a stable labour market

US labour market conditions are expected to have remained stable in May. The latest Non-Farm Payrolls data will be released on Friday, June 7th, 2024, and will provide a health check on the US jobs market.

10:09, 5 June 2024

AUD/USD analysis: Focus turns to GDP data after unexpected CPI rise

Higher-than-expected monthly CPI data watered down expectations for RBA interest rate cuts in 2024; the markets will now shift attention to quarterly GDP data on Wednesday, June 5.

15:57, 4 June 2024

ECB preview: A cut, but how many more?

After months of waiting, a rate cut from the ECB on Thursday looks like a done deal. Data from Reuters shows markets pricing in a 96% chance of a 25-basis point cut from the European Central Bank following Thursday’s policy meeting.

08:54, 4 June 2024

PCE Index Preview: Forecasts point to no change in headline or core inflation from a month earlier

The markets continue to look for signals of disinflation in the United States. The latest PCE Index data, the US Federal Reserve’s preferred inflation gauge, is released on May 31, 2024.

12:44, 29 May 2024

Gold and Silver recover from last week’s pullback but face resistance ahead of US PCE

Gold and Silver move higher after last week’s pullbacks but the precious metals are struggling with resistance ahead of the US PCE release.

15:46, 28 May 2024

People also watch

XRP/USD

0.50 Price
+4.910% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

19,677.60 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Gold

2,333.42 Price
+1.270% 1D Chg, %
Long position overnight fee -0.0190%
Short position overnight fee 0.0107%
Overnight fee time 21:00 (UTC)
Spread 0.80

ETH/USD

3,554.62 Price
+4.050% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 620,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading